login
quiescence.eu

EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment

Closed

This is the status published by the official source.

Sign in to bookmark this

Scope:This EIC Accelerator Challenge aims to improve the efficacy, safety and uptake of therapeutic approaches against refractory cancers, using novel comprehensive predictive, prognostic and companion diagnostic tests, in the context of precision oncology.
The overall goal of this Challenge is to support and accelerate the preclinical validation and/or clinical phase 1 work carried out by innovative SMEs (including start-ups, spinouts) and small midcaps to develop novel predictive, prognostic and companion diagnostic assays to guide cancer treatment. This Challenge has the following specific objectives:

• to develop novel companion diagnostic assays, including through liquid profiling to identify who, among cancer patients, is more likely to benefit from a given treatment (guided treatment);
• to develop novel predictive biomarker-based assays to identify who, among patients with potentially precancerous lesions, is more likely to develop cancer;
• to develop novel prognostic assays including through liquid profiling to identify who, among the cancer patients who underwent treatment, is more likely to recur;
• to develop novel companion diagnostic assays, including through liquid profiling to identify who, among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment and,
• to develop novel monitoring biomarker-based assays to effectively monitor the clinical course of the disease. As expected outcomes from this Challenge, clinicians will be able to:

• Identify, who among cancer patients, is more likely to benefit from a given treatment (guided treatment),
• Identify, who among patients with potentially precancerous lesions, is more likely to develop cancer,
• Identify, who among the cancer patients having underwent treatment, is more likely to recur,
• Identify who among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment, affecting their quality of life and
• More effectively monitor the clinical course of the disease. For further information, please see the EIC Work Programme 2023.

Status
Closed
Deadline
(time not stated)
Opens
Published
Grant range
€500,000 – €17,500,000
Country
European Union (EU-wide)
Programme
Horizon Europe (HORIZON)
Funder
European Commission
Official page
Open at the source portal

What applying involved

3 steps, all of them taken from this call's own documents.

This call is closed. The steps below show what applying involved, and are kept for reference only.

Understand the call

Submit

Sign in to track these

Other calls under Horizon Europe (HORIZON)

All calls under this programme

Similar opportunities

Where this came from

Source document
https://ec.europa.eu/info/funding-tenders/opportunities/data/topicDetails/horizon-eic-2023-acceleratorchallenges-01.json
Document fingerprint
229d981faf5bed9d (SHA-256, first 16 hex characters)
Collected
First recorded here

What has changed

Data source

© European Union, 2026. Source: EU Funding & Tenders Portal. Reused under Commission Decision 2011/833/EU — CC BY 4.0.

We collected this from the source on .

The source last changed this record on Thu, 15 May 2025 19:58:46 GMT.

Personal data of natural persons has been dissociated by quiescence.eu.

This service is not affiliated with, sponsored or endorsed by the data publishers.